<DOC>
	<DOCNO>NCT00235352</DOCNO>
	<brief_summary>The purpose study evaluate effect four-week trial CX516 900mg tid compare placebo upon verbal memory , attention negative symptom . The AMPA receptor positive modulator , CX516 , add stable dose clozapine , olanzapine risperidone inpatient outpatient schizophrenia . The trial intend extend replicate result previous placebo-controlled pilot trial CX516 add clozapine investigator find improvement memory attention ( moderate-to-large group effect size ) observe serious side effect . Because investigator ' pilot trial also detect two-week follow-up persistence cognitive benefit emergence large therapeutic effect upon negative symptom , trial also repeat clinical cognitive assessment follow-up , four week completion study medication evaluate persistence and/or strengthen effect .</brief_summary>
	<brief_title>Trial Ampakine Added Clozapine , Olanzapine Risperidone Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Diagnosis Schizophrenia , subtype 2 . Ages 1865 year 3 . Capable provide informed consent 4 . Stable dose clozapine , olanzapine risperidone least 6 month 1 . Serious medical neurological illness ( unstable cardiac disease , seizure disorder , malignancy , liver renal impairment , etc . ) 2 . Current substance abuse 3 . Pregnancy , nursing , unwilling use appropriate birth control measure participation female fertile 4 . Unable complete neuropsychological test 5 . History serious blood dyscrasia require discontinuation clozapine 6 . Serious suicidal homicidal risk within past six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Schizphrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>Negative Symptoms</keyword>
</DOC>